HealthQuill Alzheimer's Disease
AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to boost the North Chicago, Illinois-based company’s presence in the psychiatric and neurological disorder segment.
Drugs Health Pharma

AbbVie to acquire Cerevel for $8.7b to bolster neurological treatments

HQ Team December 7, 2023: AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to.

Read More
Experiments conducted on young adult rats have established a link between Alzheimer’s and gut microbiota, according to a global study.
Drugs Health Pharma

Scientists connect gut microbiota to Alzheimer’s disease in lab experiments

HQ Team October 19, 2023: Experiments conducted on young adult rats have established a link between Alzheimer’s and gut microbiota, according to a.

Read More
Researchers at Sweden’s Lund University have identified a new biomarker to detect Parkinson’s disease before a person develops symptoms.
Drugs Health Pharma

Swedish researchers identify new biomarker to detect Parkinson’s disease

HQ Team September 26, 2023: Researchers at Sweden’s Lund University have identified a new biomarker to detect Parkinson’s disease before a person develops.

Read More
Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for detecting Alzheimer’s disease early.
Drugs Health Pharma

Quest Diagnostics unveils direct-to-customer tests for Alzheimer’s 

HQ Team August 1, 2023: Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for.

Read More
Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of the disease, according to a company statement.
Drugs Health Pharma

Eli Lilly: Alzheimer’s test drug slows cognitive decline in early stages

HQ Team July 18, 2023: Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of.

Read More
The USFDA has granted a standard approval for Eisai and Biogen's Alzheimer injection, Leqembi —the first treatment to secure the traditional approval, paving the way for wider insurance coverage of the drug.
Drugs Health Pharma

USFDA grants green light to Eisai, Biogen’s Alzheimer’s drug Leqembi

HQ Team July 7, 2023: The USFDA has granted a standard approval for Eisai and Biogen’s Alzheimer injection, Leqembi —the first treatment to secure the.

Read More
A blood protein, called fibrin, which supports clotting, is responsible for switching on detrimental genes in Alzheimer’s disease and multiple sclerosis, researchers say.
Drugs Health Pharma

Alzheimer’s develops when hero microglia turns into a villain in brain

HQ Team June 11, 2023: A blood protein, called fibrin, which supports clotting, is responsible for switching on detrimental genes in Alzheimer’s disease.

Read More
Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority for leqembi, an investigational drug to treat early onset of Alzheimer’s disease.
Drugs Health Medical Pharma

Japan’s Eisai seeks marketing nod for Alzheimer’s drug in South Korea

HQ Team June 8, 2023: Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority.

Read More
A new artificial intelligence-driven model can analyse magnetic resonance imaging of brain scans to accurately capture cognitive decline linked to neurodegenerative diseases such as Alzheimer's.
Drugs Health Medical

Sleeping pill can delay or stop onset of Alzheimer’s; study

Suvorexant, a commonly prescribed sleeping pill to help treat insomnia reduced levels of the Alzheimer’s-associated amyloid beta protein in the brain in a.

Read More
Eiasi Co., a Japanese pharmaceutical company, has submitted a marketing authorization application for a drug, lacanemab, to treat Alzheimer's disease.
Drugs Pharma

Eiasi files market authorization for Alzheimer’s drug in Japan

Eiasi Co., a Japanese pharmaceutical company, has submitted a marketing authorization application for a drug, lacanemab, to treat Alzheimer's disease.

Read More